0001437749-24-008575.txt : 20240319
0001437749-24-008575.hdr.sgml : 20240319
20240319210140
ACCESSION NUMBER: 0001437749-24-008575
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240319
DATE AS OF CHANGE: 20240319
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AUERBACH ALAN H
CENTRAL INDEX KEY: 0001358285
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 24766031
MAIL ADDRESS:
STREET 1: 10940 WILSHIRE BLVD. SUITE 600
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-03-15
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001358285
AUERBACH ALAN H
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
1
1
President and CEO
0
Common Stock
2024-03-15
4
A
0
6577
0
A
7104320
D
Stock Option (Right to Buy)
5
2024-03-15
4
A
0
9047
0
A
2034-03-14
Common Stock
9047
9047
D
Reflects supplemental annual equity awards due to an administrative error in the calculations used to determine the original number of shares underlying the annual equity awards.
Subject to Grantee's continued status as an Employee of the Company, the Restricted Stock Units ("RSUs") shall vest with respect to one-fourth (1/4th) of the RSUs on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events.
Subject to Optionee's continued status as an Employee of the Company, Options shall vest and become exercisable with respect to one-fourth (1/4th) of the Shares subject thereto on each of July 1, 2024, January 1, 2025, July 1, 2025 and January 1, 2026, subject to acceleration in certain events.
/s/ Gordon Esplin as attorney-in-fact for Alan H. Auerbach
2024-03-19